Novo Nordisk and Schering sign research and development agreement on fertility drugs.BAGSVAERD, Denmark; BERLIN--(BUSINESS WIRE)--Sept. 24, 1996--Novo Nordisk A/S and Schering AG have entered into a long-term collaboration agreement on research and development of drugs for the treatment of infertility, as well as contraception. The agreement focuses on compounds modulating the biosynthesis Biosynthesis The synthesis of more complex molecules from simpler ones in cells by a series of reactions mediated by enzymes. The overall economy and survival of the cell is governed by the interplay between the energy gained from the breakdown of compounds of natural meiosis-activating sterols sterols (ster´ôlz), n.pl steroids having one or more hydroxyl groups and no carbonyl or carboxyl groups (e.g., cholesterol). (MAS) and compounds which activate or inhibit the MAS-dependent process of meiosis. MAS are present in women's ovaries Ovaries The female sex organs that make eggs and female hormones. Mentioned in: Choriocarcinoma ovaries (ō´v and in male testes testes or testicles Male reproductive organs (see reproductive system). Humans have two oval-shaped testes 1.5–2 in. (4–5 cm) long that produce sperm and androgens (mainly testosterone), contained in a sac (scrotum) behind the penis. . Under normal circumstances the compounds will induce the oocyte oocyte /oo·cyte/ (-sit) the immature female reproductive cell prior to fertilization; derived from an oogonium. It is a primary o. prior to completion of the first maturation division, and a secondary o. to complete meiosis, the specific cell division which results in halving the genetic material. Meiosis is a prerequisite for fertilization of the oocyte. The function of MAS in men is still unclear. The agreement also includes a basic framework for eventual manufacturing and marketing. Costs will be split equally between the parties. Both parties will have the rights to sell the products worldwide. Mads Krogsgaard Thomsen, corporate vice president, Health Care Discovery, Novo Nordisk Wikipedia is not the place for advertisement or self-advertising. Novo Nordisk (, NYSE: NVO) manufactures and markets pharmaceutical products and services. Founded in Denmark in 1923, the company has since become a world leader in diabetes care with the broadest , says, "The combination of the complimentary skills and technologies of Novo Nordisk and Schering is very important in order to improve research, development, manufacturing and marketing of fertility products. Novo Nordisk has valuable proprietary know-how and technology concerning meiosis-activating substances. And Schering has for many years been active in fertility control and has expertise in steroid chemistry as well as in reproductive biology." Professor Dr Claus Braestrup, head of research at Schering, says, "The cooperation with Novo Nordisk will provide new means for research in the fertility field. Schering has been active in contraceptive research for more than 60 years, and Novo Nordisk has valuable proprietary know-how and technology concerning meiosis-activating substances. We feel that both companies will profit from the combination of the complementary skills and technologies." Novo Nordisk A/S is the world leader in insulin production and diabetes care and is the world's largest producer of industrial enzymes. The company also manufactures and markets a variety of other pharmaceutical products. Headquartered in Denmark, Novo Nordisk employs approximately 13,400 people in 54 countries and markets its products in 130 countries. Its B shares are listed on the stock exchanges in Copenhagen, London and Zurich. Its ADSs are listed on the New York Stock Exchange New York Stock Exchange (NYSE) World's largest marketplace for securities. The exchange began as an informal meeting of 24 men in 1792 on what is now Wall Street in New York City. under the symbol "NVO NVO no visible oestrus (see no visible estrus). Called also NVE. ." Schering AG is a research based international pharmaceutical company based in Berlin whose strategy remains one of innovation. As a global player with innovative products, the company aims for leading positions in specialized markets world-wide. CONTACT: Novo Nordisk of North America North America, third largest continent (1990 est. pop. 365,000,000), c.9,400,000 sq mi (24,346,000 sq km), the northern of the two continents of the Western Hemisphere. Susan Toth Jackson, 212/867-0123 Fax: 212/986-6499 Peter Baekgaard, 212/867-0123 Fax: 212/867-0298 or Schering AG, Berlin Christine Thor-McCarthy, (+49) 30-468-1320 Raif Harenberg, (+49) 30-468-2838 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion